866-997-4948(US-Canada Toll Free)

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Nov 2012

Category :

Cancer

No. of Pages : 288 Pages

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2022

Summary

GlobalData's report "PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2022", provides comprehensive information on prostate cancer therapeutics, highlighting the treatment guidelines and identifies and analyses the key trends shaping and driving the market. The report analyses the treatment usage patterns and provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Valuable insights into the pipeline products is included. The report quantifies the unmet need in the global market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalDatas team of industry experts.

Highlights

Key Questions Answered

- How will the prostate cancer market size and composition change over the forecast period? How will the role of each therapeutic class change in the treatment of prostate cancer?
- What is the degree of unmet need among different segments of prostate cancer patients, and how will this change over the forecast period? How will pipeline drugs attempt to meet these needs?
- The two dominant therapies in the prostate cancer market will be J&Js Zytiga (abiraterone acetate) and Medivation/Astellas Xtandi (enzalutamide). Which will be the victor in each market, and why?
- What are the strengths and weaknesses of currently marketed and pipeline drugs, and how do they stack up against one another? Which will have the greatest commercial success?

Key Findings

- The launch of safe and orally administered therapies for mCRPC will drive growth in the market over the forecast period.
- New market entrants will increase competition in the mCRPC market and will decrease the level of unmet need.
- The release of Xtandi from Astellas/Medivation for refractory mCRPC patients, as well as the approval of both J&Js Zytiga and Xtandi for the chemotherapy-na
012 166
Table 74: Global Sales Forecasts ($m) for Radium-223 Chloride, 2012-2022 167
Table 75: Product Profile - Tasquinimod 168
Table 76: Tasquinimod SWOT Analysis, 2012 171
Table 77: Global Sales Forecasts ($m) for Tasquinimod, 2012-2022 172
Table 78: Product Profile - ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM) 173
Table 79: ProstVac SWOT Analysis, 2012 176
Table 80: Global Sales Forecasts ($m) for ProstVac, 2012-2022 177
Table 81: Key Companies in the Prostate Cancer, 2012 178
Table 82: AstraZenecas Prostate Cancer Portfolio Assessment, 2012 182
Table 83: AstraZenecas Prostate Cancer Portfolio SWOT Analysis, 2012 183
Table 84: Abbotts Prostate Cancer Portfolio Assessment, 2012 184
Table 85: Abbotts Prostate Cancer Portfolio SWOT Analysis, 2012 185
Table 86: Sanofis Prostate Cancer Portfolio Assessment, 2012 187
Table 87: Sanofis Prostate Cancer Portfolio SWOT Analysis, 2012 188
Table 88: J&Js Prostate Cancer Portfolio Assessment, 2012 189
Table 89: J&Js Prostate Cancer Portfolio SWOT Analysis, 2012 190
Table 90: Astellas Pharmas Prostate Cancer Portfolio Assessment, 2012 191
Table 91: Astellas Pharmas Prostate Cancer Portfolio SWOT Analysis, 2012 192
Table 92: Global Sales Forecasts ($m) for Prostate Cancer, 2012-2022 195
Table 93: Global Prostate Cancer Market - Drivers and Barriers, 2012 197
Table 94: Sales Forecasts ($m) for Prostate Cancer in the United States, 2012-2022 202
Table 95: Key Events Impacting Sales for Prostate Cancer in the US, 2012-2022 204
Table 96: Prostate Cancer Market in the US - Drivers and Barriers, 2012-2022 204
Table 97: Sales Forecasts ($m) for Prostate Cancer in France, 2012-2022 208
Table 98: Key Events Impacting Sales for Prostate Cancer in France, 2012-2022 210
Table 99: Prostate Cancer Market in France - Drivers and Barriers, 2012 211
Table 100: Sales Forecasts ($m) for Prostate Cancer in Germany, 2012-2022 213
Table 101: Key Events Impacting Sales for Prostate Cancer in Germany, 2012-2022 215
Table 102: Prostate Cancer Market in Germany - Drivers and Barriers, 2012 215
Table 103: Sales Forecasts ($m) for Prostate Cancer in Italy, 2012-2022 219
Table 104: Key Events Impacting Sales for Prostate Cancer in Italy, 2012-2022 221
Table 105: Prostate Cancer Market in Italy - Drivers and Barriers, 2012 221
Table 106: Sales Forecasts ($m) for Prostate Cancer in Spain, 2012-2022 224
Table 107: Key Events Impacting Sales for Prostate Cancer in Spain, 2012-2022 226
Table 108: Prostate Cancer Market in Spain - Drivers and Barriers, 2012 226
Table 109: Sales Forecasts ($m) for Prostate Cancer in the UK, 2012-2022 229
Table 110: Key Events Impacting Sales for Prostate Cancer in the UK, 2012-2022 231
Table 111: Prostate Cancer Market in the UK - Drivers and Barriers, 2012 231
Table 112: Sales Forecasts ($m) for Prostate Cancer in Japan, 2012-2022 235
Table 113: Key Events Impacting Sales for Prostate Cancer in Japan, 2012-2022 237
Table 114: Prostate Cancer Market in Japan - Drivers and Barriers, 2012 237
Table 115: Sales Forecasts ($m) for Prostate Cancer in Australia, 2012-2022 241
Table 116: Key Events Impacting Sales for Prostate Cancer in Australia, 2012-2022 243
Table 117: Prostate Cancer Market in Australia - Drivers and Barriers, 2012 243
Table 118: Sales Forecasts ($m) for Prostate Cancer in Canada, 2012-2022 247
Table 119: Key Events Impacting Sales for Prostate Cancer in Canada, 2012-2022 249
Table 120: Prostate Cancer Market in Canada - Drivers and Barriers, 2012 249
Table 121: Key Launch Dates 269
Table 122: Key Patent Expiries and Market Exclusivity Expiries 270
Table 123: Physicians Surveyed, By Country 285

1.2 List of Figures
Figure 1: Global Overview of Prostate Cancer, Diagnosed Five-Year Prevalent Cases in the Major Markets, 2012-2022 28
Figure 2: Global Overview of Prostate Cancer Diagnosed Incident Cases in the Major Markets, 2012-2022 29
Figure 3: General Treatment Algorithm for Prostate Cancer, 2012 35
Figure 4: Prostate Cancer Therapeutics - Clinical Trials by Country, 2012 132
Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2012-2022 135
Figure 6: Company Portfolio Gap Analysis in Prostate Cancer, 2012-2022 179
Figure 7: Global Sales for Prostate Cancer by Region, 2012-2022 196
Figure 8: Sales for Prostate Cancer in the United States by Drug Class, 2012-2022 203
Figure 9: Sales for Prostate Cancer in France by Drug Class, 2012-2022 209
Figure 10: Sales for Prostate Cancer in Germany by Drug Class, 2012-2022 214
Figure 11: Sales for Prostate Cancer in Italy by Drug Class, 2012-2022 220
Figure 12: Sales for Prostate Cancer in Spain by Drug Class, 2012-2022 225
Figure 13: Sales for Prostate Cancer in the United Kingdom by Drug Class, 2012-2022 230
Figure 14: Sales for Prostate Cancer in the Japan by Drug Class, 2012-2022 236
Figure 15: Sales for Prostate Cancer in Australia by Drug Class, 2012-2022 242
Figure 16: Sales for Prostate Cancer in Canada by Drug Class, 2012-2022 248

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *